ClinicalTrials.gg
CompletedNCT00082628Updated Jul 20, 2018Results posted

Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients

A Phase 3 interventional study of Placebo and Serostim® 4 mg in HIV Infections and Lipodystrophy, sponsored by EMD Serono. Completed at 31 sites in 2 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2018-07-20.

Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
326
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 2,803 studies in HIV Infections with a site in United States — 84 open to participants now, 141 under way, 11 of them phase 3. HIV Infections · United States.

Enrollment
380th of 2,151
326 · median 60
Started
2004
with 106 others
Phase 3
305 of 2,803
2 open now
Registered
1,329th of 2,803
by date

Among the 2,803 studies in HIV Infections with a site in United States, this one is the 380th largest by enrollment of the 2,151 interventional ones that give a count, is one of 107 that started in 2004, is one of 305 in phase 3, and was the 1,329th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

84 of the 2,803 studies in HIV Infections with a site in United States are open now. Recruiting first, the newest first:

79 more — sign in →

All 84 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,803 studies in HIV Infections with a site in United States, or all of them as a file.
02

Study summary

The primary objective of the study is to determine if Serostim® 4 mg administered daily for 12 weeks as treatment for the abnormal fat accumulation and distribution associated with HIV-associated Adipose Redistribution Syndrome (HARS) reduces Visceral Adipose Tissue (VAT, measured by CT scan) more effectively than placebo.

03

Conditions studied

  • HIV Infections
  • Lipodystrophy

Keywords

  • Growth hormone
  • Serostim®
  • Human Adipose Redistribution Syndrome
  • Human Immunodeficiency Virus lipodystrophy
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have written laboratory documentation of an infection by one of the following methods:

    • Detectable viral load measured by polymerase chain reaction (PCR) amplification, branched chain DNA (bDNA) signal amplification or the presence of p24 antigen.
    • Presence of HIV antibodies confirmed by either Western blot or immunofluorescence assay.

    Written laboratory documentation of an HIV infection must be obtained prior to randomization. In the absence of documented historical confirmation, an assay of HIV antibodies will be included in the Screening Laboratory Panel. Results will be confirmed with a Western Blot.

  2. Have evidence of excess abdominal adipose deposition when measured by the anthropometric methodology, using the following cut off values:

    • Men: Waist circumference >88.2 cm AND waist: hip ratio >= 0.95.
    • Women: Waist circumference >75.3 cm AND waist: hip ratio >= 0.9.
  3. Are taking antiretroviral medication(s) which is (are) approved or is (are) available under a Treatment IND. The regimen must have remained stable for 30 days prior to study entry. Subjects must also agree not to discontinue or to change their regimen for the duration of the study except as judged medically necessary.
  4. Have parameter values less than the following limits (using results from the central laboratory):

    • , ALT, and amylase \<= 3 times the (Screening).
    • Fasting triglycerides \<= 1,000 mg/dL (Screening).
    • Fasting glucose \<110 mg/dL (Screening).
    • Two-hour (120 minute) glucose \<140 mg/dL (Screening).
  5. Weight >= 36 kg (79.3 lb)
  6. Be between 18 and 60 years of age (inclusive) unless local law dictates different limits.
  7. Sufficiently literate in English to be able to comprehend and complete the Quality of Life Questionnaire.
  8. Willing and able to comply with the protocol for the duration of the study.
  9. Have voluntarily provided written (with subject authorization under HIPAA), prior to performing any study-related procedure that is not part of normal medical care, and with the understanding that the subject may withdraw consent at any time without prejudice to future medical care.
  10. Female subjects must:

    1. Be post menopausal (>= 1 year) or surgically sterilized (i.e., have undergone tubal ligation or hysterectomy)

      or

    2. Use a method for the duration of the study such as:

      • Hormonal contraceptive
      • Intra uterine device
      • Diaphragm with spermicide, or condom with spermicide.

      And

    3. Must be neither pregnant nor breast feeding.
    4. Confirmation that female subjects of are not pregnant must be established by a negative beta-hCG serum pregnancy test during the 14-day screening period prior to Study Day 1. If the beta-hCG serum pregnancy test is performed more than 7 days prior to Study Day 1, a urine pregnancy test must be performed by the site laboratory on Study Day 1 to confirm a negative test result.

Exclusion criteria

Exclusion Criteria:

  1. Have an active AIDS-defining opportunistic complication (OC) as defined by the CDC or have had an untreated or suspected serious systemic infection, or have had a persistent fever >= 101°F (38.3°C) during the 30 days prior to study entry.
  2. Any active or past history of , except for localized cutaneous Kaposi's sarcoma (fewer than 10 lesions, none of which are larger than 2 cm, and not on active therapy). Such exceptions must be confirmed in writing by the Serono Study Director.
  3. Have a CNS mass or active CNS process associated with neurological findings.
  4. Have unstable or untreated hypertension, defined as >= 140/90 mm Hg at the time of the Screening Visit, and/or have initiated or changed antihypertensive therapy in the 30 days prior to Study Day 1.
  5. Have an acute critical illness treated in an intensive care unit, e.g., due to complications following open heart or abdominal surgery, multiple accidental trauma, or acute respiratory failure.
  6. Have a recent history of sleep apnea or intermittent upper respiratory obstruction.
  7. Have any condition, which interferes with or protocol compliance including, but not limited to, active substance abuse and/or dementia.
  8. Are unable to comply with the Concomitant Therapy restrictions including:

    • therapy for obesity including therapy with anorexigenic or fat reducing drugs
    • anti-diabetic or insulin sensitizing medications
    • systemic
    • systemic chemotherapy, interferon or radiation therapy treatment
    • androgenic agents including, but not limited to testosterone, nandrolone, oxandrolone, oxymetholone, etc. (testosterone replacement therapy for hypogonadism is the exception to this exclusion and will be allowed if started > 30 days prior to Study Day 1)
    • progestational agents, unless used for oral or hormone replacement therapy
    • appetite stimulants
    • agents, unless approved in advance by the study medical director. Specifically, experimental antiretroviral agents are disallowed, unless available under a treatment IND or expanded access program (30 days).
    • Liposuction or other elective plastic surgery
    • AIDS wasting therapy or prior growth hormone treatment other than study drug (for 12 months prior to the screening visit)
  9. Have ever been diagnosed with any of the following conditions:

    • Pancreatitis
    • Carpal tunnel syndrome (unless resolved by surgical release)
    • Diabetes mellitus
    • Angina pectoris
    • Coronary artery disease
    • Any disorder associated with moderate to severe edema (e.g., ascites, nephrotic syndrome, congestive heart failure, lymphedema).
  10. Allergy or to growth hormone.
  11. Are participating in any other clinical studies.

In order to participate in this trial a subject must meet all of the inclusion and exclusion criteria specified above. Requests for protocol exceptions/exemptions must come from a participating, fully initiated site at which a prospective patient has consented to undergo screening. Exceptions/exemptions are only allowed by the Trial Director. There is no program in place to allow drug for a single patient IND, or for an expanded access protocol. This statement holds true for both children and adults.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
326 participants (actual)

Study arms

  • Placebo comparator
    Period I: Placebo

    Subjects will receive placebo matched to serostim® as subcutaneous injection daily for a period of 12 weeks.

    Drug: Placebo

  • Experimental
    Period I: Serostim® 4 mg

    Subjects will receive Serostim® as subcutaneous injection at a maximum dose of 4 milligram (mg) per day based on body weight for a period of 12 weeks.

    Drug: Serostim® 4 mg

  • Experimental
    Period II: Serostim® 4 mg to Placebo

    All subjects who will be initially randomized to Serostim® 4 mg arm in Period I and will receive placebo matched to Serostim® on alternate days for 24 weeks in Period II.

    Drug: Placebo

  • Experimental
    Period II: Serostim® 4 mg to Serostim® 2 mg

    All subjects who will be initially randomized to Serostim® 4 mg arm in Period I and will receive Serostim® 2 mg on alternate days for 24 weeks in Period II.

    Drug: Serostim® 2 mg

  • Experimental
    Period II: Placebo to Placebo/Serostim® 4 mg

    All subjects who will be initially randomized to Placebo arm in Period I continue receiving placebo matched to Serostim® on alternate days for 12 weeks followed by Serostim® 4 mg daily 12 weeks.

    Drug: Placebo · Drug: Serostim® 4 mg

Interventions

  • DrugPlacebo

    Placebo matched to serostim® as subcutaneous injection.

  • DrugHuman Growth HormoneStudies of Human Growth HormoneHuman Growth Hormone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Serostim® as subcutaneous injection at a maximum dose of 4 milligram (mg) per day based on body weight.

    Also known as: recombinant human growth hormone (r-hGH)

  • DrugHuman Growth HormoneStudies of Human Growth HormoneHuman Growth Hormone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Serostim® 2 mg as subcutaneous injection on alternate days.

    Also known as: recombinant human growth hormone (r-hGH)

06

What researchers measure

Primary outcomes

  1. Treatment Period I: Change From Baseline in Absolute Area of Visceral Adipose Tissue (VAT) at Week 12

    Absolute area of VAT was measured by cross-sectional computed tomography (CT) scan at the level of the L4-5 inter-vertebral disk. CT scanning was to be used to assess the cross sectional area of abdominal fat and its distribution between the visceral and subcutaneous compartments, as measured at L4-L5.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Treatment Period I: Change From Baseline in Trunk Fat at Week 12

    Changes in trunk fat was measured as changes in mass (kg) on Dual-Energy X-Ray Absorptiometry (DXA) Scan.

    Time frame: Baseline, Week 12

  2. Change From Baseline in Patient Reported Outcome of Body Image Distress at Week 12

    Body image distress was assessed on a scale ranging from 0 to 100, where 0 = Extremely Upsetting and 100 = Extremely Encouraging.

    Time frame: Baseline, Week 12

  3. Treatment Period I: Change From Baseline in Non- High-density Lipoprotein (Non-HDL) Cholesterol at Week 12

    Lipid profile data was analyzed for Non-HDL Cholesterol.

    Time frame: Baseline, Week 12

  4. Treatment Period II: Failure Rate at Week 36 Based on Visceral Adipose Tissue (VAT) For Subjects Who Received Serostim® 4 mg in Period I

    Failure rate based on VAT was assessed by CT scan at L4-L5. The failure rate was defined as the percentage of subjects who regained \>50% of their VAT lost in Treatment Period I. This outcome was to be assessed for subjects who received Serostim® 4 mg in Period I.

    Time frame: Week 36

07

Results

Posted Jul 20, 2018

Participant flow

Treatment Period I (Week 1 to Week 12)
Participant flow — Treatment Period I (Week 1 to Week 12)
MilestonePeriod I: PlaceboPeriod I: Serostim® 4 mgPeriod II: Serostim® 4 mg to PlaceboPeriod II: Serostim® 4 mg to Serostim® 2 mgPeriod II: Placebo to Placebo/Serostim® 4 mg
Started81245000
Completed73185000
Not completed860000
Withdrew: Subjects did not receive study drug01000
Withdrew: Subjects without post-baseline assessmen21000
Withdrew: Subjects did not complete week 12543000
Withdrew: Did not continue to period ii115000
Treatment Period II: Week 12 to Week 36
Participant flow — Treatment Period II: Week 12 to Week 36
MilestonePeriod I: PlaceboPeriod I: Serostim® 4 mgPeriod II: Serostim® 4 mg to PlaceboPeriod II: Serostim® 4 mg to Serostim® 2 mgPeriod II: Placebo to Placebo/Serostim® 4 mg
Started00939273
Completed00787655
Not completed00151618
Withdrew: Lost to follow-up00001
Withdrew: Withdrawal by subject00010
Withdrew: Subjects did not complete week 3600151517

Outcome measures

PrimaryTreatment Period I: Change From Baseline in Absolute Area of Visceral Adipose Tissue (VAT) at Week 12

Absolute area of VAT was measured by cross-sectional computed tomography (CT) scan at the level of the L4-5 inter-vertebral disk. CT scanning was to be used to assess the cross sectional area of abdominal fat and its distribution between the visceral and subcutaneous compartments, as measured at L4-L5.

Time frame:
Baseline, Week 12
Reported as:
Mean · Square Centimeter (cm^2)
Treatment Period I: Change From Baseline in Absolute Area of Visceral Adipose Tissue (VAT) at Week 12
Square Centimeter (cm^2)Period I: PlaceboPeriod I: Serostim® 4 mg
Treatment Period I: Change From Baseline in Absolute Area of Visceral Adipose Tissue (VAT) at Week 120.5 ± 34.5-32.6 ± 37.9
Statistical analysis
  • Period I: Placebo vs Period I: Serostim® 4 mg · Nonparametric ANCOVA Model · p = <0.001
SecondaryTreatment Period I: Change From Baseline in Trunk Fat at Week 12

Changes in trunk fat was measured as changes in mass (kg) on Dual-Energy X-Ray Absorptiometry (DXA) Scan.

Time frame:
Baseline, Week 12
Reported as:
Mean · Kilogram (Kg)
Treatment Period I: Change From Baseline in Trunk Fat at Week 12
Kilogram (Kg)Period I: PlaceboPeriod I: Serostim® 4 mg
Treatment Period I: Change From Baseline in Trunk Fat at Week 120.2 ± 1.3-2.2 ± 1.7
SecondaryChange From Baseline in Patient Reported Outcome of Body Image Distress at Week 12

Body image distress was assessed on a scale ranging from 0 to 100, where 0 = Extremely Upsetting and 100 = Extremely Encouraging.

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline in Patient Reported Outcome of Body Image Distress at Week 12
units on a scalePeriod I: PlaceboPeriod I: Serostim® 4 mg
Change From Baseline in Patient Reported Outcome of Body Image Distress at Week 120.23 ± 1.420.10 ± 1.73
SecondaryTreatment Period I: Change From Baseline in Non- High-density Lipoprotein (Non-HDL) Cholesterol at Week 12

Lipid profile data was analyzed for Non-HDL Cholesterol.

Time frame:
Baseline, Week 12
Reported as:
Mean · milligram/deciliter (mg/dL)
Treatment Period I: Change From Baseline in Non- High-density Lipoprotein (Non-HDL) Cholesterol at Week 12
milligram/deciliter (mg/dL)Period I: PlaceboPeriod I: Serostim® 4 mg
Treatment Period I: Change From Baseline in Non- High-density Lipoprotein (Non-HDL) Cholesterol at Week 12-2.8 ± 28.1-13.0 ± 37.1
SecondaryTreatment Period II: Failure Rate at Week 36 Based on Visceral Adipose Tissue (VAT) For Subjects Who Received Serostim® 4 mg in Period I

Failure rate based on VAT was assessed by CT scan at L4-L5. The failure rate was defined as the percentage of subjects who regained \>50% of their VAT lost in Treatment Period I. This outcome was to be assessed for subjects who received Serostim® 4 mg in Period I.

Time frame:
Week 36
Reported as:
Number · percentage of subjects
Treatment Period II: Failure Rate at Week 36 Based on Visceral Adipose Tissue (VAT) For Subjects Who Received Serostim® 4 mg in Period I
percentage of subjectsPeriod II: Serostim® 4 mg to PlaceboPeriod II: Serostim® 4 mg to Serostim® 2 mg
Treatment Period II: Failure Rate at Week 36 Based on Visceral Adipose Tissue (VAT) For Subjects Who Received Serostim® 4 mg in Period I53.740.3

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Period I: Placebo (Week 1 to 12)—2/81 (2.5%)70/81 (86.4%)
Period I: Serostim® 4 mg (Week 1 to 12)—3/244 (1.2%)244/244 (100%)
Period II: Serostim® 4 mg to Placebo (Week 12 to 36)—3/93 (3.2%)46/93 (49.5%)
Period II: Serostim® 4 mg to Serostim® 2 mg (Week 12 to 36)—2/92 (2.2%)48/92 (52.2%)
Period II: Placebo to Placebo (Week 12 to Week 24)—2/73 (2.7%)14/73 (19.2%)
Period II: Placebo to Serostim® 4 mg (Week 24 to 36)—1/73 (1.4%)73/73 (100%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventPeriod I: Placebo (Week 1 to 12)Period I: Serostim® 4 mg (Week 1 to 12)Period II: Serostim® 4 mg to Placebo (Week 12 to 36)Period II: Serostim® 4 mg to Serostim® 2 mg (Week 12 to 36)Period II: Placebo to Placebo (Week 12 to Week 24)Period II: Placebo to Serostim® 4 mg (Week 24 to 36)
Groin abscessInfections and infestations0/810/2440/930/921/730/73
PneumoniaInfections and infestations0/810/2440/930/921/730/73
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/810/2440/930/920/731/73
DepressionPsychiatric disorders1/810/2440/930/920/730/73
Abdominal painGastrointestinal disorders1/810/2440/930/920/730/73
PneumoniaInfections and infestations0/810/2440/931/920/730/73
DiarrhoeaInfections and infestations0/810/2440/931/920/730/73
Pancreatic insufficiencyInfections and infestations0/810/2440/931/920/730/73
NephrolithiasisRenal and urinary disorders0/810/2440/931/920/730/73
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/810/2441/930/920/730/73
Most frequent other events
Showing 10 of 25
Most frequent other events
EventPeriod I: Placebo (Week 1 to 12)Period I: Serostim® 4 mg (Week 1 to 12)Period II: Serostim® 4 mg to Placebo (Week 12 to 36)Period II: Serostim® 4 mg to Serostim® 2 mg (Week 12 to 36)Period II: Placebo to Placebo (Week 12 to Week 24)Period II: Placebo to Serostim® 4 mg (Week 24 to 36)
Oedema peripheralGeneral disorders4/81113/2444/936/920/7334/73
ArthralgiaGeneral disorders14/8195/2445/938/922/7330/73
Pain in extremityGeneral disorders3/8146/2445/932/922/7319/73
MyalgiaGeneral disorders3/8134/2440/930/920/7314/73
Upper respiratory tract infectionGeneral disorders6/8113/24415/937/920/730/73
HeadacheGeneral disorders3/8139/2444/935/920/738/73
Blood glucose increasedGeneral disorders2/8133/2443/936/922/7311/73
HypoaesthesiaGeneral disorders0/8134/2441/935/920/738/73
HyperglycaemiaGeneral disorders1/8117/2440/930/922/7310/73
Musculoskeletal stiffnessGeneral disorders1/8118/2440/930/921/739/73

Baseline characteristics

The modified ITT Population (ITT) for Period I was defined as all subjects who had a baseline and at least one post-baseline efficacy measurement.

Age, Continuous
Age, Continuous(Years)Period I: PlaceboPeriod I: Serostim® 4 mgTotal
Mean45.5 ± 7.544.5 ± 7.044.8 ± 7.1
Sex: Female, Male
Sex: Female, Male(Participants)Period I: PlaceboPeriod I: Serostim® 4 mgTotal
Female113647
Male68207275
08

Study locations

31 sites
  • University of Alabama/Birmingham
    Birmingham, Alabama 35294, United States
  • CARE CLINIC - UCLA Medical Center
    Los Angeles, California 90095, United States
  • 1401 N. Palm Canyon
    Palm Springs, California 92262, United States
  • Trials Unit Div of Infectious and Immunologic Diseases
    Sacramento, California 95817, United States
  • UCSD - AntiViral Research Center
    San Diego, California 92103, United States
  • University of California, San Francisco - Div. of Endocrinology
    San Francisco, California 94110, United States
  • Kaiser Permanente
    San Francisco, California 94118, United States
  • Northern California Institute for Research and Education, Inc.
    San Francisco, California 94121, United States
  • Harbor-UCLA Medical Ctr Research & Education Institute
    Torrance, California 90502, United States
  • AIDS Alliance
    West Hollywood, California 90069, United States
  • University of Colorado Health Sciences Center
    Denver, Colorado 80262, United States
  • 1640 Rhode Island Avenue, N.W.
    Washington, D.C., District of Columbia 20036, United States
  • Office Of Dr Gary Richmond
    Fort Lauderdale, Florida 33316, United States
  • 3661 South Miami Avenue
    Miami, Florida 33133, United States
  • Care Resources
    Miami, Florida 33137, United States
  • Infectious Disease Associates
    Sarasota, Florida 34239, United States
  • AIDS Research Consortium of Atlanta
    Atlanta, Georgia 30308, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Indiana University Infectious Disease Research Clinic
    Indianapolis, Indiana 46202, United States
  • Tufts University School of Medicine
    Boston, Massachusetts 02111, United States
  • Community Research Initiative of New England
    Boston, Massachusetts 02215, United States
  • Community Research Initiative Of New England
    Springfield, Massachusetts 01107, United States
  • Hennepin County Medical Center
    Minneapolis, Minnesota 55415, United States
  • Albany Medical College
    Albany, New York 12208, United States
  • Weill Medical College of Cornell Universtiy
    New York, New York 10021, United States
  • St. Luke's Roosevelt Hospital
    New York, New York 10025, United States
  • Bronx Women's Interagency HIV Study
    The Bronx, New York 10467, United States
  • Central Texas Clincial research
    Austin, Texas 78705, United States
  • IDP Research
    Annandale, Virginia 22003, United States
  • Office of Daniel Coulston, M.D.
    Spokane, Washington 99204, United States
  • AIDS Research Program
    Vancouver, British Columbia V6Z 1Y6, Canada
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2004 to primary completion in Sep 2005, 16 months.

Results were first posted in Jul 2018, 12 years 9 months after primary completion.

Of 57 industry-sponsored phase 3 interventional studies under HIV Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 16 months is below that.

Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2004
First posted
May 17, 2004
StartActual
May 28, 2004
Primary completionActual
Sep 28, 2005
CompletionActual
Sep 28, 2005
Results first posted
Jul 20, 2018
Last update
Jul 20, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00082628
Lead sponsor
EMD Serono
Responsible party
Sponsor
First posted
May 17, 2004
Start date
May 28, 2004
Primary completion
Sep 28, 2005
Completion
Sep 28, 2005
Results posted
Jul 20, 2018
Last update
Jul 20, 2018

Study contacts

Medical Responsible
study director · EMD Serono Inc., a business of Merck KGaA, Darmstadt, Germany
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion